Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Chlortetracycline→

Chlortetracycline Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
57-62-5
Molecular formula
C22H23ClN2O8
Molecular weight
478.9 g/mol
Drug class
Tetracycline-class antibiotic (veterinary medicinal use)
Mechanism of action
Primarily bacteriostatic. Reversibly binds the bacterial 30S ribosomal subunit at the aminoacyl-tRNA acceptor site, preventing aminoacyl-tRNA binding and inhibiting protein synthesis.
Indications / reported uses
  • Veterinary medicinal uses only in the cited authorisations; approved species and indications depend on product. Examples include treatment or control of susceptible bacterial enteritis and respiratory infections in food-producing animals, and local treatment of superficial wounds. Do not infer a human therapeutic indication.

Sources: Merck Veterinary Manual — Tetracyclines in animals · Canadian Food Inspection Agency chlortetracycline hydrochloride approved claims · UK VMD veterinary product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Chlortetracycline Environmental Risk Assessment (ERA) (the Chlortetracycline ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.